Philip Morris International (PM) has disclosed a new risk, in the Regulation category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Philip Morris International faces heightened U.S. business risk because its growth in smoke-free products (SFPs) relies on an evolving and uncertain legal and regulatory framework. FDA authorizations for IQOS and ZYN products are subject to stringent marketing, reporting, and compliance obligations and can be modified, suspended, or withdrawn, especially if youth or non-user uptake increases. Moreover, future product iterations may not receive the necessary premarket or modified-risk approvals, constraining innovation and portfolio expansion. Any compliance failures or legal disputes at the federal, state, or local level could delay or disrupt commercialization, materially affecting the company’s revenues, cash flows, and profitability in the U.S. market.
The average PM stock price target is $178.00, implying -2.63% downside potential.
To learn more about Philip Morris International’s risk factors, click here.